Planned and maintained Kanban and
safety stock programs for multiple Customer accounts in a contract manufacturing environment.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs;
safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase
program due to changes in its
stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The authors tracked the
stock market performance of 17 CHAA applicants or recipients with proven health and / or
safety programs using six investment modeling scenarios.
«Study strengthens link between
stock market performance and employee health and
safety programs.»
Since its inception in June 1992, the
safety program has expanded from its initial focus on Indy cars to encompass
stock...
Essential Defensive Driving GM
Safety Agency Leather
Stocking Defensive Driving Employee Advantage Catholic Charities of Chenango Chase «2» Driving School WNC Crossroads Driving
Programs LLC
Director of Quality Assurance of a mid-sized food processing company for the financial results of the department of Quality Assurance and
Safety, and its goals and objectives of protecting the company, its stock holders, employees, customers, and consumers through systemic quality assurance, safety, and regulatory pr
Safety, and its goals and objectives of protecting the company, its
stock holders, employees, customers, and consumers through systemic quality assurance,
safety, and regulatory pr
safety, and regulatory
program.
Drove technology advancements to enable over $ 300M working capital efficiencies through advanced Planning ERP releases vending machine consignment vendor co-located inventory DTC
safety stock optimization S&OP and CPFR automation for Verizon network and FiOS materials * Delivered Sourcing transformation
program driving over $.5 B savings via key
programs including spend analytics contract compliance Enterprise Supplier insig...
Professional Duties & Responsibilities Directed operations of Target Stores generating $ 20 million in annual revenue Created and implemented strategies to cut expenses while increasing sales Assisted corporate leadership with store marketing and branding efforts Hired, trained, managed, and reviewed more than 130 team members Enhanced employee value through professional development
programs Increased employee dedication through recognition and team building initiatives Managed logistics team operations including product unloading and
stocking Oversaw planogram, pricing, instocks, backroom, and replenishment teams Created an attractive and impactful salesfloor ensuring steady sales Coordinated all salesfloor transitions, salesplanner, signage, and pricing sets Ensured the highest levels of customer service resulting in repeat business Served as liaison between Target leadership and construction contractors Guaranteed store
safety, security, and branding during remodel Built strong, long - term relationships with business partners, coworkers, and employers Completed all duties in a positive, professional, and timely manner Fostered an environment of respect and dedication to company goals
Entropic Ltd. (Kildare, Ireland) 12/2007 — 07/2009 HVAC Engineer & Technical Sales • Served as project manager of HVAC and heat recovery equipment design, sales, and installation for large scale commercial and residential applications • Created specifications for ventilation and heat recovery equipment for multiple clients including AVIVA Stadium DKIT Engineering building and Genzyme Waterford • Utilized expertise and communication skills as liaison between customers and suppliers • Trained and supervised sales, customer service, and technical staff ensuring effective operations • Developed proficiencies in computer
programs such as AutoCAD and in - house design
programs • Employed LEAN techniques to maximize project efficacy in a
safety conscious manner • Oversaw
stock control, order entry, and timely delivery of products
Wisconsin's new law moves much of the 340B savings for which affected
safety - net family planning sites are eligible over to the state Medicaid
program itself, with the intent to curb these providers» ability to
stock and dispense affordable contraceptive methods.